| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8317721 | Clinical Biochemistry | 2012 | 9 Pages |
Abstract
⺠Dialysis patients have increased plasma homocysteine (Hcy) and cardiovascular events. ⺠Hcy-lowering therapy benefits in nondiabetic end-stage renal disease (ESRD) patients. ⺠Folic acid fortification may weaken the therapeutic effects of Hcy-lowering therapy. ⺠A simple mathematical model to explain the experimental observations. ⺠Comorbid conditions may influence the effect of Hcy-lowering therapy in ESRD patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Chia-Chao Wu, Cai-Mei Zheng, Yuh-Feng Lin, Lan Lo, Min-Tser Liao, Kuo-Cheng Lu,